Background: Familial hypercholesterolemia is a human monogenic disease caused by populationspecific mutations in the low density lipoprotein (LDL) receptor gene. Despite thirteen different mutations of the LDL receptor gene were reported from Russia prior to 2003, the whole spectrum of disease-causing gene alterations in this country is poorly known and requires further investigation provided by the current study.
from the Baltic Sea region. Only four mutations (c.313+1G>A, c.651-653del3, C308Y and W422X) were recurrent as all those were found in two unrelated families. By this study the number of known mutations in the LDL receptor gene in St.-Petersburg area was increased nearly threefold. Analysis of all 34 low density lipoprotein receptor gene mutations found in St.-Petersburg argues against strong founder effect in Russian familial hypercholesterolemia.
Background
Familial hypercholesterolemia (FH) (OMIM #143890) is one of the most common monogenic human diseases. It is inherited as an autosomal dominant trait with the prevalence of the heterozygous form conventionally considered to be about 1 of 500 in most populations [1] . Elevated blood serum cholesterol is due to impaired removal of low-density lipoproteins (LDL) from blood by LDL receptors, and it is associated with early onset coronary artery disease and myocardial infarction. Impairment of LDL receptor function usually results either from the absence or deficiency of the LDL receptor (OMIM *606945) itself or from a common mutation (R3500Q) in the gene of the receptor's ligand, apolipoprotein B (OMIM +107730) causing type B of the autosomal dominant hypercholesterolemia (OMIM #144010) [2] . Furthermore, a third type of monogenic autosomal dominant hypercholesterolemia (OMIM #603776) is due to the recently discovered defects in the proprotein convertase PCSK9 gene (OMIM *607786) [3] . A form of recessively inherited hypercholesterolemia (OMIM #603813) has a prevalence of less than 1:10 000000 and is due to defects in the LDL receptor adaptive protein ARH (OMIM *605747) [4, 5] . Even though many forms of monogenic hypercholesterolemia are known, only apoB gene and LDL receptor gene variations seem to contribute significantly to the CHD morbidity in most populations [6] .
The spectrum of LDL receptor mutations varies between different human populations and more than 900 mutations in the LDL receptor gene have been characterized worldwide [7] [8] [9] . A recent review [9] shows a clear difference in the LDL receptor gene mutations spectra for Western European countries, but this review gives nearly no data on the genetics of FH in the Eastern European countries and Russia. However, many mutations were described from Poland [10] and Bulgaria [11] and already thirteen different LDL receptor gene mutations have been published from the Russian population prior to 2003 [12] . In the present research we expand the study of the molecular genetic basis for FH in St.-Petersburg known to be the most well studied region of Russia in respect to FHcausing mutations and report 21 mutations, previously unknown in Russia.
Methods

Patients
Patients with FH were recruited from two lipid clinics of St.-Petersburg, namely Institute of Human Brain and Institute of Experimental Medicine. The clinical diagnosis of familial hypercholesterolemia was based on the following criteria: highly elevated plasma total cholesterol and LDL-cholesterol, presence of tendon xanthomata, corneal arcus or both, and positive family history of myocardial infarction and hypercholesterolemia with at least one first-degree relative affected. Forty-five probands fulfilling at least two of three criteria listed above were selected for the study. Full data of patients including their lipid data are given in the Discussion section (see Table 2 ). Informed consent was obtained in each case for DNA testing procedures.
Biochemical procedures
Genomic DNA was extracted from blood white cells using a standard method [13] . The patients were initially tested for the apoB mutation R3500Q by restriction fragment length analysis [14] . Exons of the LDL receptor gene were then amplified [15] , and PCR products were subjected to gel-electrophoresis followed by ethidium bromide or silver staining of DNA to exclude non-specific amplification. Single-strand conformation polymorphism (SSCP) analysis was performed in an ABI 377 DNA Sequencer (PEApplied Biosystems) sequencing device using 4,25% nondenaturing MDE polyacrylamide gels (Cambrex) at 20°C. The gels were run under two different conditions, i.e. standard MDE gel or with the addition of 5% glycerol to the MDE gel. Automated DNA sequencing was performed in part in the ABI 377 DNA Sequencer (PE-Applied Biosystems), in part in an ALFExpress-2 DNA sequencer (Amersham Life Sciences), using primers for routine PCR DNA amplification. In the case of samples bearing the deletions, PCR products were cloned into a commercially available vector (TACLONE, Medigen, Novosibirsk) and sequenced using universal and reverse primers.
Results
None of the 45 patients had the apoB R3500Q mutation, whereas 25 patients had mutations in the LDL receptor gene. Large genomic rearrangements in the LDL receptor gene were previously shown to be an uncommon cause of FH in St.-Petersburg [16] and had been excluded in most patients of the current group. Therefore we restricted our search to point mutations and to minor deletions and insertions. We identified 21 sequence variations (Table 1) of which two probably were not pathogenic (in the following considerations we give numbering of aminoacids in the LDL receptor according to Yamamoto's nomenclature, [17] ). The T705I mutation (known also as FH Paris -9) is not associated with elevated serum cholesterol [18] , and the transition c.1617C>T (P518P) is synonymous. We consider the remaining 19 variations to be pathogenic. Eleven mutations have been described in other populations, but to our knowledge the remaining 8 mutations have not been described so far [7, 8] . From two of these nucleotide substitutions (C249X and W422X) the stop codon arises, four are frame-shift mutations leading to premature stop codons (FsK202:S205X; FsK290:N309X; FsV409:S423X; FsV597:A622X), and two result in amino acid substitutions (D601N and C646S). Sequencing of the cloned mutant allele bearing the fivenucleotide deletion (c.936-940del5 or FsE291) is demonstrated on Fig. 1 . Mutations c.313+1G>A, c.651-653del3, C308Y and W422X were found in two probands each.
Rapid tests were developed for most of the mutations and all of those were confirmed by using these methods (Table  1) . Various detection methods, including heteroduplex analysis, restriction enzyme tests and SSCP for several mutations from the list are illustrated by Figures 2, 3 . Cosegregation of the mutations and elevated blood serum cholesterol was demonstrated in seventeen families (see Fig. 2, 3 and Table 1 ). Totally the mutations were confirmed in 9 relatives and excluded in 27 members of the proband's families. Most important the diagnosis of FH was excluded in 9 and set in 2 children of probands before adulthood, i.e. prior to age 18. In these children mutation detection was of crucial importance to set the diagnosis and to suggest further life style.
In case of the Q12X mutation, the c.97C>T transition leads to occurrence of a new Mae I restriction site (CTAG) in exon 2 that allows a simple detection of this mutation. Restriction enzyme test was performed for the proband and her 4 descendants (Fig. 2) . The presence of the mutation was confirmed in the son of the proband and excluded in the daughter and two grandchildren.
In some other mutations no restriction enzyme tests can be developed for their rapid detection. For example, it is true for the recurrent mutation IVS3+1G>A (c.313+1G>A) that was identified by means of SSCP and verified by sequencing in probands from two unrelated families. SSCP patterns on silver-stained gels differ strikingly in patients with and without the mutation. The presence of the mutation was confirmed in the son of the proband by SSCP. In heterozygotes a deletion of 41 nucleotides at c.1291-1331 in exon 9 (mutation FsV409:S423X) results in occurrence of specific heteroduplexes. Besides, a PCR fragment of smaller size as compared to the normal allele is revealed in silver-stained polyacrylamide gels (Fig. 3) . This mutation was identified in the son and daughter of the proband and excluded in the second daughter and in her child (Fig. 3) .
Discussion
Previously 13 mutations in the LDL receptor gene have been reported in FH patients residing in St.-Petersburg [12] (see Table 3 ). Among pathogenic mutations reported here, eleven have been described in other populations (Table 1 ) [7, 8] , and eight are novel. Six of the novel mutations lead to premature stop codons and result in truncated protein chains that probably lose their function. One out of these truncating mutations (c.936-940del5 or FsE291) also changes invariant nucleotides nearby exon-intron junction and thus may affect splicing. The D601N missense mutation, causing substitution of aspartic acid by asparagine has not been reported before. It seems likely that such a substitution might cause the loss of function since one other mutation in the same codon (D601Y) was described in familial hypercholesterolemia subjects [7] . The C646S also has not been reported before, but 5 other mutations affecting this codon have been described, one of which, C646Y (FH French Canadian-2), results in a transport defective protein (mutation class 2A) [21] . We, therefore, find it very likely that the C646S mutation is also pathogenic, but expression studies are needed to justify the effect of both missense mutations D601N and C646S. Previously described mutations were considered to be pathogenic due mostly to their listing in FH mutation databases even though functional studies were not systematically performed. Indeed, V806I mutation (known as variant FH New York -5) [22] occurs in the LDL receptor internalization signal NPVY, for which the consensus sequence NPxY is given (where X is not a conserved aminoacid) [23] and thus the substitution of isoleucin for valine may be not crucial for the LDL receptor function. The V776M mutation may have effect on LDL receptor mRNA splicing rather than to be realized on the protein level since the V776M mutation changes the invariant G at the 3' end of exon 16. However, this mutation is likely to be pathogenic since it was reported already in patients from La Habana, Cuba [24] .
Detection of mutation c.1291-1331del41 (mutation FsV409:S423X) of the LDL receptor gene by means of PCR product sizing and heteroduplex analysis The apoB R3500Q mutation was not detected in any of our patients. This finding is in agreement with the previous observation that the R3500Q mutation had not been found in St.-Petersburg [25] . The mutation has been detected in another part of Russia only in 2 of 71 patients with symptoms of familial hypercholesterolemia [26] . The apoB R3500Q mutation is almost exclusively found in Caucasian individuals, and almost all subjects with the mutation carry the same haplotype. One of the highest frequencies of the mutation has been found in the Swiss population (approximately 1/200) [27] , and Miserez and Muller [27] hypothesized that the mutation may have arisen in Switzerland 10,000 -6,000 years ago. The prevalence of the mutation declines with increasing distance from the Central Europe [27, 28] , and the prevalence of the apoB R3500Q mutation is therefore expected to be In our study we were able to find LDL receptor gene pathogenic mutations in 23 of 45 patients. Many methods are considered to be superior to routine isotopic SSCP when screening for mutations in DNA (see e.g. [33] for comparison of SSCP and DHPLC). However, we believe that mutations could have been overlooked due to intrinsic limitations of SSCP method in our hands only in few cases. Fluorescent SSCP, used in the current study, can be superior even to DHPLC and is a sensitive method for mutation screening, especially when different gel electrophoresis conditions are applied [34] . Recent studies indicate, that SSCP run under two different conditions detect up to 96% of heterozygous variations (P.H. Nissen, unpublished results). In our study LDL receptor gene mutations were found in 56% (14 out of 26) patients selected by SSCP and in 53% (10 out of 19) patients which DNA was subjected to direct sequencing of all gene exons (Table 2) . We do not find it likely that many patients are underdiagnosed due to presence of large genomic rearrangements. In a study conducted in St.-Petersburg, in the partly overlapping sample of FH patients, only one case of a large deletion was found in the sample of 50 probands, giving the rough estimate of genomic rearrangements 2% [16] . In fact in mixed populations (such as that of that of St. Petersburg) the contribution of large rearrangements to the spectrum of pathogenic mutations seems to vary from 6% in Great Britain [35] to 2.5% in English-speaking Canadians [36] . More important, some of intronic mutations leading to defects of splicing could be missed, since the design of primers [15] mostly following recommendations of Hobbs et al. [22] with the only exclusion for primers to amplify exon 3 allowed analyzing only 14 out of 34 intron-exon boundaries in the LDL receptor gene. Recent investigation [37] demonstrated that a high percent of previously missed LDL receptor mutations may be localized in introns. In the cited study [37] in the patient sample after modifying the gene analysis procedure nearly 27% of patients turned out to have intronic mutations, despite the functional significance of these mutations have still to be validated.
In the apoB gene we only looked for the R3500Q mutation, and the possibility that other mutations in that gene are responsible for hyperlipidemia cannot be ruled out. This possibility is unlikely, since the apoB gene has been studied extensively in other laboratories and no other pathogenic variants have been determined. To conclude we cannot definitely rule out the possibility that some undiscovered mutations in the LDL receptor gene have not been found. However, the possibility that the patients have mutations in a different gene involved in FH still remains since the mutation in the PCSK9 gene [3] were not tested in this study.
With the two exceptions, mutations previously reported from Russia [12, 38] have been confined to a single family. The exceptions were the mutations G197del (FH-Lithuania), found in high percent of Ashkenazi Jewish families with FH from St.-Petersburg [39] , and the C139G mutation found in two Slavic families from St.-Petersburg [40, 12] , one family in Novosibirsk [38] and one family in Moscow [41] . In this study 4 mutations, namely c.313+1G>A, c.651-653del3, C308Y and W422X were found in two unrelated families. Together with the previous findings we discovered 34 mutations in the LDL receptor gene in St. Petersburg of which only six were detected in more than one family. Fourteen LDL receptor gene mutations were discovered by the other Russian FH team from Moscow, Russia out of which only C139G is shared with St.-Petersburg population [12, 41] . To date a total of 47 different FH mutations are known from Russia. The data presented here enlarge the spectrum of mutations found in the Russian population and make us regard it as genetically heterogeneous.
Conclusions
We identified nineteen pathogenic mutations in the LDL receptor gene in 23 probands and two probably neutral mutations. In our study only four mutations in the LDL receptor gene (c.313+1G>A, c.651-653del3, C308Y and W422X) were found to be recurrent, i.e. all of those were found in two apparently unrelated families. Together with the data obtained earlier [12, 38] our results present an evidence against the strong founder effect among Russian FH patients, and it is likely that in the St.-Petersburg area there is as much genetic heterogeneity as in most other areas of the world.
